CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

12 Mar 2025 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

06 Mar 2025 07:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

03 Mar 2025 15:58:05 By NetDania Notify

Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

20 Feb 2025 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting

10 Feb 2025 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference

04 Feb 2025 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

28 Jan 2025 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

22 Jan 2025 07:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

20 Dec 2024 09:46:04 By NetDania Notify

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

19 Dec 2024 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

25 Nov 2024 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

12 Nov 2024 16:05:01 By Nasdaq GlobeNewswire

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

07 Nov 2024 09:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

06 Nov 2024 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

04 Nov 2024 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

31 Oct 2024 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

22 Oct 2024 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

09 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

27 Aug 2024 07:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

12 Aug 2024 16:05:00 By Nasdaq GlobeNewswire